key: cord-0072591-2oojgkm5
authors: Joshi, Seema; Smith, Zachary; Soman, Sana; Jain, Saniya; Yako, Atheel; Hojeij, Marwa; Massoud, Louis; Alsaadi, Ayman; Williams, Jonathan; Kenney, Rachel; Miller, Joseph; Alangaden, George; Ramesh, Mayur
title: Low versus High Dose Methylprednisolone in Adult Patients with COVID-19: Less is More
date: 2021-12-08
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofab619
sha: 497d2549b362f93e72f1a7498a7f5fbd174f872b
doc_id: 72591
cord_uid: 2oojgkm5

BACKGROUND: Corticosteroids use in severe COVID-19 improves survival; however, the optimal dose is not established. We aim to evaluate clinical outcomes in patients with severe COVID-19 receiving high-dose corticosteroids (HDC) versus low-dose corticosteroids (LDC). METHODS: This was a quasi-experimental study conducted at a large, quaternary care center in Michigan. A corticosteroid dose change was implemented in the standardized institutional treatment protocol on 17 November 2020. All patients admitted with severe COVID-19 that received corticosteroids were included. Consecutive patients in the HDC group (1 September to 15 November 2020) were compared to the LDC group (30 November 2020 to 20 January 2021). HDC was defined as methylprednisolone 80 mg daily in two divided doses and LDC was defined as methylprednisolone 32-40 mg daily in two divided doses. The primary outcome was all-cause 28-day mortality. Secondary outcomes included progression to mechanical ventilation, hospital length of stay (LOS), discharge on supplemental oxygen, and corticosteroid-associated adverse events. RESULTS: Four-hundred and seventy patients were included; 218 (46%) and 252 (54%) in the HDC and LDC groups, respectively. No difference was observed in 28-day mortality (14.5% vs 13.5%, p=0.712). This finding remained intact when controlling for additional variables (OR 0.947, [CI 0.515-1.742], p=0.861). Median hospital LOS was 6 and 5 days in the HDC and LDC groups, respectively (p<0.001). No differences were noted in any of the other secondary outcomes. CONCLUSIONS: Low-dose methylprednisolone had comparable outcomes including mortality to high-dose methylprednisolone for the treatment of severe COVID-19.

The use of corticosteroids in hospitalized hypoxic patients with Coronavirus Disease 2019 has become the standard of care based on improvement in clinical outcomes from a robust body of literature. [1] [2] [3] [4] [5] It is well known that pharmacodynamic differences exist between corticosteroids and their effects vary when different doses are utilized. 6 Early reports from China described a mortality benefit with methylprednisolone in patients with COVID-19 and acute respiratory distress syndrome (ARDS). 7 Based on this information, in March 2020 our center initiated a protocol using methylprednisolone 80 mg daily (1 mg per kg) for patients with severe COVID-19. 8 Methylprednisolone was selected as the corticosteroid due to prior trial data in ARDS, favorable pharmacokinetic properties, and pharmacogenomic data suggesting it may be the optimal corticosteroid in COVID-19. [9] [10] [11] [12] After publication of randomized clinical trials in the subsequent months, evidence-based guidelines (such as the NIH treatment guidelines) recommended adopting trial regimens or administering an alternate corticosteroid at an equivalent glucocorticoid dose (Supplement Table 1 ). 1 Based on these recommendations, in November 2020, our center modified treatment protocol to a lower dose of methylprednisolone 32-40 mg daily (0.5 mg per kg).

Although corticosteroids improve outcomes in severe COVID-19, the optimal dose is undefined. Methylprednisolone has been used in varying doses ranging 40 to 500 mg per day. 4, 13, 14, 15 This study compares outcomes, including 28-day mortality, of high versus low dose methylprednisolone within our standardized institutional treatment protocol in those with severe COVID-19.

Patients were eligible for inclusion in this study if they were admitted to Henry Ford Hospital (HFH), age > 18 years, laboratory confirmed SARS-CoV-2, and had severe COVID-19 defined as hypoxia requiring supplemental oxygen. 16 Patients who were excluded from this study were those who died within 24 hours, received less than 48 hours of corticosteroids, and lack of 28-day follow up.

A confirmed case of COVID-19 was defined as having a positive reverse-transcription polymerase chain reaction (RT-PCR) assay for SARS-CoV-2 by nasopharyngeal sample.

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t 6 Primary Outcome

The primary outcome was all-cause 28-day mortality. Twenty-eight-day mortality data was available through updated medical records and all patients were cross-referenced with data from the Michigan Health Information Network. 17 Secondary Outcome

Secondary outcomes were progression to mechanical ventilation, length of hospital stay, discharge on supplemental oxygen and corticosteroid-associated adverse events (bacteremia, hospital-acquired pneumonia/ventilator-associated pneumonia, candidemia, and hyperglycemia).

Healthcare associated infections were defined by standard National Healthcare Safety Network criteria. 18 Hyperglycemia was defined as glucose greater than 200 mg/dL and with additional insulin use.

We reported continuous variables as median and interquartile range (IQR) and performed comparisons using the Mann-Whitney U test or t-test, as appropriate. Categorical data was reported as number and percentage (no., %) and comparisons were performed using the χ2 test or Fisher exact test, as appropriate. No imputation was made for missing data points. A 2-sided α < 0.05 was considered statistically significant. We performed bivariable and a priori multivariable logistic regression analysis to test the association between 28-day mortality and exposure to the HDC or LDC protocol. Covariates in the bivariable analysis with a p-value <0.1 and clinical rationale were included in the multivariable regression model that was restricted to an event-to-variable ratio of 10:1. We constructed a Kaplan Meier curve that plotted the proportion of patients who survived over 28-days based on their exposure to the HDC or LDC protocol (Supplemental Figure 1 ). Statistical analysis was performed using IBM SPSS version 25 (Chicago, IL) and SAS 9.4 (Cary, NC).

During the study period, there were 784 patients admitted who were diagnosed with COVID- Median duration of hospital length of stay was 6 days and 5 days in the HDC and LDC groups (p<0.001). Other secondary outcomes including need for mechanical ventilation and supplemental oxygen upon discharge were similar. Corticosteroid associated adverse events were comparable.

In a cohort of patients with severe COVID-19 treated with methylprednisolone, a reduction in dose did not impact 28-day mortality. Our mortality rates were lower than those reported in randomized trials done early in the pandemic and may reflect differences in study populations and improvement in supportive care over time. [19] [20] [21] [22] No differences were observed in corticosteroidassociated adverse events between groups similar to previous reports with varying corticosteroid doses. 3, 5 Rates of hyperglycemia were similar to clinical trials that included comparable patients with diabetes. 20 Methylprednisolone doses greater than 1.36 mg per kg per day have been associated with worse outcomes. 23 Both groups in the current study received a lower dose than this threshold.

Without evidence of superior efficacy with high dose methylprednisolone, it seems prudent to use the minimal effective dose until more data is available. 24 Dexamethasone, hydrocortisone, and methylprednisolone have been studied in COVID-19 clinical trials. [3] [4] [5] The largest trial to date that first reported the benefits of corticosteroids in COVID-19

utilized a regimen of dexamethasone 6 mg daily for up to 10 days. 19 Many guidelines adopted this trial regimen as the preferred corticosteroid regimen for COVID-19. If an alternate corticosteroid is used it A c c e p t e d M a n u s c r i p t 8 is recommended to provide a daily dose equivalent to dexamethasone 6 mg. 1 However, limited data from smaller trials have reported that methylprednisolone may be the preferred corticosteroid when compared to dexamethasone, but the total corticosteroid dose equivalency between the two agents has varied. 25,26 These preliminary findings support a pharmacogenomic analysis suggesting that methylprednisolone may be the optimal corticosteroid. 12 Future research is warranted to identify if corticosteroid agents selection may play a role in patient outcomes.

Most patients in the present study received oral methylprednisolone during their treatment course within a day of hospitalization for a median duration of 5 days. A majority of randomized clinical trials for COVID-19 utilized intravenous corticosteroids. 3 Our finding that oral corticosteroids are efficacious is consistent with previous literature. 19 Duration of corticosteroid use in randomized trials for COVID-19 ranged from 5 to 14 days. 3 The median duration of corticosteroids treatment in the present study was shorter by two days compared to trials that allowed for discontinuation of corticosteroid upon symptom resolution. 19 These findings highlight the importance of early initiation of oral methylprednisolone in severe COVID-19 and utilizing a short course when symptoms resolve.

The current study has limitations. A quasi-experimental study design was used due to the changes in methylprednisolone dosing in the early and later months of the pandemic. However, methylprednisolone usage in COVID-19 was consistent due to the use of a standardized institutional protocol with a clear time point of when methylprednisolone dosing was reduced. A wash out period of two weeks was used between study groups to allow clinicians to adjust to the new dosing. Notably, the mortality rate in our present study remained similar to our earlier study in March 2020 suggesting minimal effect of maturation bias. 8 Our results are limited in that they are from real world clinical practice and unmeasured confounding cannot be ruled out.

In conclusion, an early, short course of low dose oral methylprednisolone in hospitalized patients with severe COVID-19 had comparable outcomes to high dose methylprednisolone. Further research is needed to clarify an optimal corticosteroid dose while the world continues to face threats of COVID-19 variants.

Patient Consent Statement: This study does not include factors necessitating patient consent as it is based on an observational cohort (pre post study design).

The design of the work has been approved by the institutional review board of the Henry Ford Health System. M a n u s c r i p t 

National Institute of Health. COVID-19 Treatment Guidelines: Corticosteroids

Surviving Sepsis Campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19)

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis

Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes: Systematic Review and Meta-analysis

Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Crit Care

Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19

Prolonged low-dose methylprednisolone treatment is highly effective in reducing duration of mechanical ventilation and mortality in patients with ARDS

Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients' data from four randomized trials and trial-level meta-analysis of the updated literature

Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS

COVID-19: disease pathways and gene expression changes predict methylprednisolone can improve outcome in severe cases

Methylprednisolone and 60 Days in Hospital Survival in Coronavirus Disease

Therapeutic Application of Corticosteroids in COVID-19: A Focus on Optimum Dose and Duration of Therapy

Corticosteroid therapy for severe COVID-19 pneumonia: optimal dose and duration of administration. Glob Health Med

COVID-19 Treatment Guidelines: Oxygenation and Ventilation

The Impact of Sociodemographic Factors, Comorbidities, and Physiologic Responses on 30-Day Mortality in Coronavirus Disease 2019 (COVID-19) Patients in Metropolitan Detroit

Dexamethasone in Hospitalized Patients with Covid-19

Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial

Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial

A c c e p t e d M a n u s c r i p t 10